| Clinical Publications |
Scientific Publications |
| March 2021 |
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience
Pepe S et al. Leuk Lymphoma, March 2021
(epub ahead of print) |
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogeneic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B
Bencome-Alvarez AE, Oncogene, March 2021
(epub ahead of print)
– open access publication
|
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world setting in France: The POST-PACE study
Etienne G et al. Leuk Res, March 2021 (epub ahead of print) |
Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of CML progression
Sloma I et al. Haematologica, March 2021
– open access publication
|
|
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
Scalzulli E et al. Ann Hematol, March 2021
(epub ahead of print)
|
Discovery of a novel CIP2A variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias
Makela E et al. Clin Cancer Res, March 2021
(epub ahead of print)
– open access publication |
| |
The discovery of novel BCR-ABL tyrosine kinase inhibitors using a pharmacophore modelling and virtual screening approach
Huang TT et al. Front Cell Dev Biol, March 2021
– open access publication |
| February 2021 |
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKI’s: First interim analysis of OPTkIMA study
Malagola M et al. Cancer Med, February 2021
(epub ahead of print)
- open access publication |
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
Clark RE et al. Blood Adv, February 2021
- open access publication |
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR – final report from AFTER-SKI
Richter J et al. Leukemia, February 2021
(epub ahead of print)
– open access publication |
Eradicating residual chronic myeloid leukemia: basic research lost in translation
Zhao H and Deininger M. Lancet Haematol, February 2021 |
Mortality rates in patients with chronic myeloid leukemia in chronic phase with frontline second generation kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)
Breccia M et al. Ann Hematol, February 2021 |
Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFTM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib
Hrdinova T et al. Int J Oncol, February 2021 |
Dose-optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: A new therapeutic challenge
Iurlo A et al. J Clin Med, February 2021 – open access publication
|
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells
Ozkan T et al. Leuk Res, February 2021
(epub ahead of print)
|
Bosutinib in the real-life treatment of chronic myeloid leukemia patients >65 years resistant/intolerant to previous tyrosine-kinase inhibitors
Latagliata R et al. Hematol Oncol, February 2021
(epub ahead of print)
|
Circulating miR-1461 expression to imatinib in adult chronic myeloid leukemia
Habib EM et al. J Investig Med, February 2021 |
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Garcia-Gutiérrez V et al. Blood Cancer J, February 2021
– open access publication
|
Future approaches for treating chronic myeloid leukemia: CRISP therapy
Vuelta E et al. Biology(Basel), February 2021
– open access publication |
|
MR4 log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial
Seguro FS et al. Leuk Res, February 2021
|
Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells
Yahata T et al. Haematologica, February 2021
– open access publication |
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Efficace F et al. Expert Rev Hematol, February 2021
(epub ahead of print)
|
Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: is there a correlation?
Frikha R et al. J Oncol Pharm Pract, February 2021
(epub ahead of print) |
| |
The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: A systematic review and meta-analysis
Ghalesardi OK et al. Leuk Res, February 2021
|
| |
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
Lu T et al. Eur J Pharmacol, February 2021
(epub ahead of print) |
| January 2021 |
Clinical outcomes of patients with chronic myeloid leukemia with concurrent core binding factor rearrangement and Philadelphia chromosome
Morita K et al. Clin Lymphoma Myeloma Leuk,
January 2021 (epub ahead of print) |
The giant HECT E3 ubiquitin ligase HERC1 is aberrantly expressed in myeloid related disorders and it is a novel BCR-ABL1 binding partner
Ali MS et al. Cancers(Basel), January 2021
– open access publication |
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed CML in chronic phase: ENESTnd 10-year analysis
Kantarjian HM et al. Leukemia, January 2021
(epub ahead of print) – open access publication |
Genetic screening for potential new targets in chronic myeloid leukemia based on Drosophia Transgenic for human BCR-ABL
Lo Iacono M et al. Cancers(Basel), January 2021
– open access publication |
ILong-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukemia: results from the French SPIRIT phase III randomised trial
Guilhot F et al. Leukemia, January 2021
(epub ehead of print) |
The quiescent fraction of chronic myeloid leukemia stem cells depends on BMPR1B, STAT3, and BMP4-niche signals to persistent in patients in remission
Jeanpierre S et al. Haematologica, January 2021
– open access publication |
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
Colafigli G et al. Crit Rev Oncol Hematol, January 2021 |
HLA polymorphis are associated with treatment-free remission following discontinuation of TKI’s in CML
Ureshino H et al. Mol Cancer Ther, January 2021 |
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia in patients treated with nilotinib
Caocci G et al. Ann Hematol, January 2021
(epub ahead of print) |
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTor pathway in combination with TKIs: A review
Singh P et al. Med Oncol, January 2021 |
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data
Gambarcoti-Passerini C et al. Eur J Haematol, January 2021 – open access publication |
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration
Ito F et al. Int J Hematol, January 2021 |
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real-life
Santoleri F et al. Curr Med Res Opin, January 2021
(epub ahead of print) |
NT157, an IGF1R-IRS1/2 inhibitor exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia
Scopim-Ribeiro R et al. Invest New Drugs, January 2021 (epub ahead of print) |
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukemia in the United Kingdom: the UK TARGET CML study
Milojkociv D et al. Br J Haematol, January 2021
– open access publication |
|
BCR-ABL kinase domain mutation analysis by Next Generation Sequencing detected additional mutations in CML patients with suboptimal response to Nilotinib
Benjamin ESB et al. Leuk Lymphoma, January 2021
(epub ehead of print) |
|
English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
